))
Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists
«
»
32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2
Manage episode 403727189 series 3525243
Innhold levert av David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.
Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.
Key Insights:
- Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.
- Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape.
- Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown.
Connect with Thomas Rexer:
LinkedIn: https://www.linkedin.com/in/thomas-rexer
Website: www.eversyn.de
Next Step:
Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com
59 episoder
Del
